04-15-2019 08:17 PM CET - Health & Medicine
Print

Antipsychotic Drugs Market: Huge Growth Opportunities | Industry Trends | Market Analysis & Global Forecast to 2025

Press release from: Allied Market Research



Antipsychotic drugs are also termed as major tranquilizers or neuroleptics and these are primarily used to treat psychosis. The common psychotic disorders, where these drugs are majorly used include schizophrenia, hallucinations, delusions, bipolar disorder, and others. The antipsychotic drugs market is expected to grow due to the rising number of Schizophrenic patients. However, patent expiration of major brands could negatively impact market growth.

Download the Sample Report @ bit.ly/2v6L4X2

Deep-dive analysis of global antipsychotic drugs market focuses on major market dynamics such as drivers, restraints, and opportunities. Competitive landscape section profiles the key players on the basis of business performance, strategic moves and SWOT analysis. Profound analysis of segments would be helpful to understand the product distribution trends in each segment within the global antipsychotic drugs market.

High prevalence of Schizophrenia and psychotic disorders are the prime drivers for global antipsychotic drugs market. Increased drug abuse, over-prescription of drugs and addiction to antipsychotic drugs, are the additional factors that drive the market growth for antipsychotic drugs. However, patent expiry of major brands over the past few years had a negative impact on market growth and it has been responsible for the rising competition from a generic drug manufacturer. Serious side effects such as tardive dyskinesia, associated with antipsychotics also restraints market growth. Emerging economies are the opportunistic markets for antipsychotics due to a large pool of aging population, which has a high risk of psychosis, and increased healthcare awareness.

Global Antipsychotic Drugs Market by Brands

The global antipsychotic drugs market is segmented into three categories based on brands such as First, Second and Third generation antipsychotic drugs. Except for Halodol and lithium carbonate, all first-generation antipsychotic agents are called as standard or typical antipsychotics, as they act similar i.e., interference with neurotransmitters. Second generation antipsychotics are also known as atypical antipsychotic agents and act as broad-spectrum antagonists of dopamine, serotonin and alpha-noradrenergic receptors. With the development of technology and growing competition to gain the largest market share, researchers are focusing on first-generation antipsychotics to better understand their working mechanism. Abilify and Seroquel are topmost marketed brands due to their high therapeutic efficacy and reduced side effects.

Purchase the Report @20% Discount: bit.ly/2IBsRZp

Global Antipsychotic Drugs Market by Application

The global antipsychotic drugs are used to treat different brain disorders such as Schizophrenia, Bipolar disorder, Dementia, Unipolar Depression and Others. The drugs used in Schizophrenia and psychotic depression are expected to boost the growth of antipsychotic drugs market due to increasing incidences of these two conditions.

Global Antipsychotic Drugs Market by Geography

Geographically, the global antipsychotic drugs market is segmented into North America, Europe, Asia-Pacific, and LAMEA. Antipsychotics are the largely prescribed drugs in the North American region due to large patient pool suffering from mental and psychotic disorders. Asia-Pacific and LAMEA are the lucrative markets for global antipsychotic drugs manufacturers, due to the large patient pool and rising healthcare awareness.

Competitive Landscape

The key players within the global antipsychotic drugs market include Eli Lilly, AstraZeneca, Pfizer, Bristol-Myers Squibb, GlaxoSmithKline, and Johnson & Johnson. Patent expiration of major brands such as Zyprexa (by Eli Lilly) and Seroquel (by AstraZeneca) has negatively impacted the total revenue of this market. Generic competition is soaring due to the patent expiration of six largest antipsychotic drugs in 2012.

High-Level Analysis

The comprehensive analysis of global antipsychotic drugs market provides an overview of the market and its key concerns. Market segmentation is concentric towards product distribution trends of each segment that would be helpful to strategist in deciding on the market segments. Market dynamics covers market drivers, restraints and opportunities, which would help to understand the market behavior. Porter’s Five Forces analysis would be helpful in determining market profitability. Buyers bargaining power is high for global antipsychotic drugs market due to patent expiration of major brands and availability of many generic medicines in the marketplace. Global antipsychotic drugs market has a high threat from new entrants as major brands have lost their patent protection in 2012. Industrial rivalry is intense due to the entry of numerous generic competitors, which forces big players to manipulate their drug prices according to changing market trends.

KEY BENEFITS

This report offers the following benefits in particular:

Complete analysis of drivers restraints and opportunities within the global antipsychotic drugs market would assist professionals to understand the market behavior

Profound assessment of geography focuses on niche market areas and provides a forward-looking perspective

Porter’s Five Forces framework would assist strategist in decision making by analyzing the market profitability within global antipsychotic drugs market

Comprehensive assessment of key leaders and their market strategies for global antipsychotic drugs market would be informative to professionals in the corporate sector

KEY DELIVERABLES

The global antipsychotic drugs market is segmented into two major categories such as technology and geography.

MARKET BY BRANDS

First Generation Drugs (Standard / Typical Antipsychotic Agents)

Thorazine (Chlorpromazine HCl)

Serentil (Mesoridazine Besylate)

Mellaril (Thioridazine HCl)

Haldol (Haloperidol)

Loxitane (Loxapine Succinate)

Trilafon (Perphenazine)

Navane (Thiothixene)

Sordinol (Clopenthixol)

Others

Second generation Drugs (Atypical Antipsychotic Agents)

Zyprexa (Olanzapine)

Geodon (Ziprasidone)

Seroquel (Quetiapine)

Risperdal (Risperidone)

Clozaril (Clozapine)

Invega (Paliperidone)

Asendin (Amoxapine)

Latuda (Lurasidone)

Others

Third generation Drugs

Abilify (Aripiprazole)

MARKET BY APPLICATION

Schizophrenia

Bipolar Disorder

Dementia

Unipolar Depression

Other

About Us:-

Allied Market Research (AMR) is a full-service market research and business consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions.” AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.
We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.

Contact Us:-

David Correa
5933 NE Win Sivers Drive
#205, Portland, OR 97220
United States
USA/Canada (Toll Free):
+1-800-792-5285, +1-503-894-6022, +1-503-446-1141
UK: +44-845-528-1300
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060
Fax: +1(855)550-5975
help@alliedmarketresearch.com
Web: www.alliedmarketresearch.com

This release was published on openPR.
News-ID: 1703887 • Views: 330
More releasesMore releases

You can edit or delete your press release here: